Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BYSINASDAQ:PIRSNASDAQ:RAINNASDAQ:VLON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBYSIBeyondSpring$2.52+0.4%$1.99$0.98▼$3.44$101.19M0.0732,333 shs19,596 shsPIRSPieris Pharmaceuticals$13.60$15.17$6.20▼$18.68$17.95M0.6183,101 shs51,728 shsRAINRain Enhancement Technologies Holdco$3.15+7.4%$1.21$0.82▼$11.32$23.89M-0.2211,768 shs4,867 shsVLONVallon Pharmaceuticals$1.35$0.67$0.21▼$12.92$18.20M-1.145.78 million shs27,318 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBYSIBeyondSpring+0.40%-18.97%+44.91%+75.00%+3.28%PIRSPieris Pharmaceuticals0.00%0.00%0.00%0.00%+55.96%RAINRain Enhancement Technologies Holdco+2.09%-3.93%-30.15%+47.38%+142.15%VLONVallon Pharmaceuticals0.00%-3.57%+12.50%-77.00%-54.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBYSIBeyondSpringN/AN/AN/AN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBYSIBeyondSpring 0.00N/AN/AN/APIRSPieris Pharmaceuticals 0.00N/AN/AN/ARAINRain Enhancement Technologies Holdco 0.00N/AN/AN/AVLONVallon Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBYSIBeyondSpring$1.75M58.06N/AN/A($0.37) per share-6.81PIRSPieris Pharmaceuticals$42.81M0.42N/AN/A$21.66 per share0.63RAINRain Enhancement Technologies HoldcoN/AN/AN/AN/A($0.96) per shareN/AVLONVallon Pharmaceuticals$100K182.01N/AN/A$0.18 per share7.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBYSIBeyondSpring-$11.12MN/A0.00∞N/AN/AN/AN/AN/APIRSPieris Pharmaceuticals-$24.54M-$12.10N/A∞N/A-39.71%-80.93%-59.55%N/ARAINRain Enhancement Technologies Holdco-$4.53MN/A0.00∞N/AN/AN/A-43.86%N/AVLONVallon Pharmaceuticals-$7.02M-$0.78N/A∞N/AN/A-230.48%-124.89%N/ALatest RAIN, PIRS, BYSI, and VLON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025RAINRain Enhancement Technologies HoldcoN/A-$0.20N/A-$0.20N/AN/A5/12/2025Q1 2025BYSIBeyondSpringN/A-$0.06N/A$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBYSIBeyondSpringN/AN/AN/AN/AN/APIRSPieris PharmaceuticalsN/AN/AN/AN/AN/ARAINRain Enhancement Technologies HoldcoN/AN/AN/AN/AN/AVLONVallon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBYSIBeyondSpringN/A2.492.49PIRSPieris PharmaceuticalsN/A4.824.82RAINRain Enhancement Technologies HoldcoN/A0.090.09VLONVallon PharmaceuticalsN/A2.292.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBYSIBeyondSpring40.29%PIRSPieris Pharmaceuticals40.11%RAINRain Enhancement Technologies Holdco25.79%VLONVallon Pharmaceuticals8.74%Insider OwnershipCompanyInsider OwnershipBYSIBeyondSpring29.31%PIRSPieris Pharmaceuticals6.39%RAINRain Enhancement Technologies Holdco17.40%VLONVallon Pharmaceuticals37.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBYSIBeyondSpring8040.32 million28.50 millionOptionablePIRSPieris Pharmaceuticals1401.32 million1.24 millionOptionableRAINRain Enhancement Technologies Holdco637.59 million6.27 millionNo DataVLONVallon Pharmaceuticals313.48 million8.45 millionNot OptionableRAIN, PIRS, BYSI, and VLON HeadlinesRecent News About These CompaniesQuestcor Pharmaceuticals,July 21, 2023 | forbes.comVallon Pharmaceuticals' shareholders approve reverse merger with California companyApril 20, 2023 | bizjournals.comVallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock SplitApril 20, 2023 | finance.yahoo.comVallon Pharmaceuticals Adjourns Special Meeting of Stockholders Until April 20, 2023April 12, 2023 | finance.yahoo.comLab Notes: CHOP gets $10M research gift; Vallon seeks greater shareholder support for mergerApril 7, 2023 | bizjournals.comVallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ETApril 4, 2023 | finance.yahoo.comVallon Pharmaceuticals Inc.: Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finanznachrichten.deVallon Pharmaceuticals Reports Fiscal Year 2022 Financial ResultsFebruary 24, 2023 | finance.yahoo.comIs Vallon Pharmaceuticals Inc (VLON) recent surge justifiedFebruary 14, 2023 | benzinga.comVallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch EventJanuary 11, 2023 | finance.yahoo.comSHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Vallon Pharmaceuticals, Inc. - VLONDecember 27, 2022 | benzinga.comVallon rockets as it announces merger with GRI BioDecember 15, 2022 | thepharmaletter.comTSay goodbye to Vallon as a low-profile NKT cell startup steps into its battered shoes on NasdaqDecember 14, 2022 | endpts.comEVallon Pharmaceuticals to merge with California biotech firm in 'best path forward'December 14, 2022 | bizjournals.comWhat's Going On With Vallon Pharmaceuticals Stock Today?December 14, 2022 | msn.comWhy Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving PremarketDecember 14, 2022 | benzinga.comVallon Pharmaceuticals and GRI Bio Enter into Merger Agreement with Goal of Advancing Innovative Pipeline of NKT Cell RegulatorsDecember 13, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comVallon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateJuly 28, 2022 | finance.yahoo.comVallon Pharmaceuticals, Inc. (VLON)July 19, 2022 | finance.yahoo.comMedia Sentiment Over TimeRAIN, PIRS, BYSI, and VLON Company DescriptionsBeyondSpring NASDAQ:BYSI$2.52 +0.01 (+0.40%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.49 -0.03 (-1.19%) As of 06/26/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.Pieris Pharmaceuticals NASDAQ:PIRSPieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.Rain Enhancement Technologies Holdco NASDAQ:RAINAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Vallon Pharmaceuticals NASDAQ:VLONVallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
